{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:24:59Z","timestamp":1790717099323,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T00:00:00Z","timestamp":1376697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T00:00:00Z","timestamp":1376697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["U01 CA97452, U10 CA98543"],"award-info":[{"award-number":["U01 CA97452, U10 CA98543"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GCRC","award":["M01-RR00188-46"],"award-info":[{"award-number":["M01-RR00188-46"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1002\/pbc.24605","type":"journal-article","created":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T07:46:39Z","timestamp":1376725599000},"page":"452-456","source":"Crossref","is-referenced-by-count":140,"title":["Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group"],"prefix":"10.1002","volume":"61","author":[{"given":"Brenda","family":"Weigel","sequence":"first","affiliation":[{"name":"University of Minnesota; Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Malempati","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; Oregon Health & Science University; Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[{"name":"Mayo Clinic and Foundation; Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan D.","family":"Voss","sequence":"additional","affiliation":[{"name":"Children's Hospital-Boston and Dana Farber Cancer Institute; Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.","family":"Cho","sequence":"additional","affiliation":[{"name":"Johns Hopkins Hospital; Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen X.","family":"Chen","sequence":"additional","affiliation":[{"name":"National Cancer Institute; Rockville Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine; USC Keck School of Medicine; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doojduen","family":"Villaluna","sequence":"additional","affiliation":[{"name":"Children's Oncology Group Operations Center; Monrovia California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Adamson","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Blaney","sequence":"additional","affiliation":[{"name":"Texas Children's Cancer Center\/Baylor College of Medicine; Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,17]]},"reference":[{"key":"10.1002\/pbc.24605-BIB0001|pbc24605-cit-0001","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","volume":"8","author":"Pollak","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1002\/pbc.24605-BIB0002|pbc24605-cit-0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1054\/ghir.2001.0244","article-title":"Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein","volume":"11","author":"Ayalon","year":"2001","journal-title":"Growth Horm IGF Res"},{"key":"10.1002\/pbc.24605-BIB0003|pbc24605-cit-0003","first-page":"325","article-title":"Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors","volume":"1","author":"El-Badry","year":"1990","journal-title":"Cell Growth Differ"},{"key":"10.1002\/pbc.24605-BIB0004|pbc24605-cit-0004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jcb.20046","article-title":"IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma","volume":"92","author":"MacEwen","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1002\/pbc.24605-BIB0005|pbc24605-cit-0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI114243","article-title":"Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II","volume":"84","author":"El-Badry","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1002\/pbc.24605-BIB0006|pbc24605-cit-0006","doi-asserted-by":"crossref","first-page":"30822","DOI":"10.1074\/jbc.272.49.30822","article-title":"The insulin-like growth factor-I receptor is required for EWS\/FLI-1 transformation of fibroblasts","volume":"272","author":"Toretsky","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1002\/pbc.24605-BIB0007|pbc24605-cit-0007","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1073\/pnas.90.12.5828","article-title":"Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product","volume":"90","author":"Werner","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/pbc.24605-BIB0008|pbc24605-cit-0008","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1210\/edrv-16-2-143","article-title":"Molecular and cellular aspects of the insulin-like growth factor I receptor","volume":"16","author":"LeRoith","year":"1995","journal-title":"Endocr Rev"},{"key":"10.1002\/pbc.24605-BIB0009|pbc24605-cit-0009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(03)00159-9","article-title":"The insulin-like growth factor system and cancer","volume":"195","author":"LeRoith","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1002\/pbc.24605-BIB0010|pbc24605-cit-0010","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1158\/0008-5472.CAN-04-3192","article-title":"Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors","volume":"65","author":"Scotlandi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0011|pbc24605-cit-0011","doi-asserted-by":"crossref","first-page":"6772","DOI":"10.1158\/1078-0432.CCR-06-1479","article-title":"Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo","volume":"12","author":"Tanno","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0012|pbc24605-cit-0012","first-page":"961","article-title":"Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice","volume":"135","author":"Gansler","year":"1989","journal-title":"Am J Pathol"},{"key":"10.1002\/pbc.24605-BIB0013|pbc24605-cit-0013","first-page":"1222","article-title":"The anti insulin-like growth factor I receptor (IGF1-R) antibody AVE1642 exhibits anti-tumor activity against neuroblastoma cell lines and xenografts","volume":"47","author":"Geoeger","year":"2006","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0014|pbc24605-cit-0014","first-page":"5073","article-title":"An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation","volume":"63","author":"Maloney","year":"2003","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0015|pbc24605-cit-0015","first-page":"1790","article-title":"Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells","volume":"7","author":"Benini","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0016|pbc24605-cit-0016","first-page":"8912","article-title":"A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo","volume":"63","author":"Burtrum","year":"2003","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0017|pbc24605-cit-0017","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/0008-5472.CAN-05-3126","article-title":"Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer","volume":"66","author":"Sachdev","year":"2006","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0018|pbc24605-cit-0018","doi-asserted-by":"crossref","first-page":"5549s","DOI":"10.1158\/1078-0432.CCR-07-1109","article-title":"IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor","volume":"13","author":"Rowinsky","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0019|pbc24605-cit-0019","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/1078-0432.CCR-06-0443","article-title":"Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors","volume":"12","author":"Wu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0020|pbc24605-cit-0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00262-006-0196-9","article-title":"Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis","volume":"56","author":"Wu","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1002\/pbc.24605-BIB0021|pbc24605-cit-0021","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/0008-5472.CAN-06-2000","article-title":"Insulin-like growth factor-I receptor signaling blockade combined with radiation","volume":"67","author":"Allen","year":"2007","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0022|pbc24605-cit-0022","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1158\/1078-0432.CCR-05-2691","article-title":"Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma","volume":"12","author":"Wang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24605-BIB0023|pbc24605-cit-0023","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/pbc.22367","article-title":"Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program","volume":"54","author":"Kolb","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24605-BIB0024|pbc24605-cit-0024","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/jco.2007.25.18_suppl.3505","article-title":"A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monocolonal antibody, in patients with advanced solid tumors","volume":"25","author":"Higano","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24605-BIB0025|pbc24605-cit-0025","unstructured":"Rothenberg ML Poplin E Sandler AB Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors 2007"},{"key":"10.1002\/pbc.24605-BIB0026|pbc24605-cit-0026","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","article-title":"Phase I\/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing Sarcoma: A report from the Children's Oncology Group","volume":"30","author":"Malempati","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24605-BIB0027|pbc24605-cit-0027","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/sim.1653","article-title":"On the estimation of the binomial probability in multistage clinical trials","volume":"23","author":"Jung","year":"2004","journal-title":"Stat Med"},{"key":"10.1002\/pbc.24605-BIB0028|pbc24605-cit-0028","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/pbc.24605-BIB0029|pbc24605-cit-0029","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0959-8049(94)00509-4","article-title":"A new 123I-MIBG whole body scan scoring method-Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma","volume":"31A","author":"Ady","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1002\/pbc.24605-BIB0030|pbc24605-cit-0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1470-2045(09)70354-7","article-title":"Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study","volume":"11","author":"Olmos","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.24605-BIB0031|pbc24605-cit-0031","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.10000","article-title":"Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study","volume":"28","author":"Pappo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24605-BIB0032|pbc24605-cit-0032","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1158\/1535-7163.MCT-07-2401","article-title":"Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake","volume":"7","author":"Shang","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1002\/pbc.24605-BIB0033|pbc24605-cit-0033","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1158\/1535-7163.MCT-11-0235","article-title":"Akt\/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody","volume":"10","author":"Shin","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1002\/pbc.24605-BIB0034|pbc24605-cit-0034","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/pbc.23157","article-title":"Combination testing (Stage 2) of the anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the Pediatric Preclinical Testing Program","volume":"58","author":"Kolb","year":"2012","journal-title":"Pediatr Blood Cancer"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24605","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.24605\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T10:31:48Z","timestamp":1625394708000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24605"}},"subtitle":["Phase 2 Study of Cixutumumab"],"short-title":[],"issued":{"date-parts":[[2013,8,17]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.24605","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8,17]]}}}